Percutaneous Coronary Intervention News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Abbott’s Absorb fares well again against Xience in Japanese study
Abbott (NYSE:ABT) today released positive data from a Japanese study of its Absorb fully dissolving heart stent that pitted it against its own Xience permanent drug eluting stent. The results were announced at the European Society of Cardiology’s annual meeting in London. The 400 patient multi-center, randomized Absorb study, published in the European Heart Journal, set out to compare the safety and effectiveness of the 2 stents in patients with coronary artery disease. The study reported a rate of target lesion failure, the primary endpoint of the trial, of 4.2% for the Absorb stent and 3.8% for its Xience stent at...
Source: Mass Device - September 1, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Drug-Eluting Stents Abbott Source Type: news

Ticagrelor administered in the ambulance reduces ischaemic events 24 hours after PCI
Ticagrelor administered in the ambulance reduces ischaemic events 24 hours after primary percutaneous coronary intervention (PCI), according to new findings. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 31, 2015 Category: Science Source Type: news

News from the European Society of Cardiology Conference (FREE)
By the Editors Here's a quick look at some of the major news that came out of the European Society of Cardiology Congress in London this weekend:Cyclosporine Before Percutaneous Coronary Intervention? Among patients with acute anterior … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 31, 2015 Category: Primary Care Source Type: news

Cyclosporine does not improve outcomes after PCI
(European Society of Cardiology) The immunosuppressant drug cyclosporine did not improve clinical outcomes compared to placebo in patients receiving percutaneous coronary intervention for the more severe form of heart attack known as ST-segment elevation myocardial infarction. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 30, 2015 Category: Global & Universal Source Type: news

Percutaneous Coronary Intervention Outcomes Worse in RA, SLE (CME/CE)
(MedPage Today) -- Overall mortality after PCI higher in rheumatoid arthritis and lupus (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 29, 2015 Category: Cardiology Source Type: news

ESC guidelines recommend radial approach for percutaneous coronary interventions in ACS
(European Society of Cardiology) For the first time, ESC guidelines published today give the highest degree of recommendation for the radial approach over the femoral one for coronary angiography and percutaneous coronary intervention in patients with acute coronary syndromes (ACS). The ACS without persistent ST-segment elevation guidelines, drafted by an international multidisciplinary Task Force, are published online in European Heart Journal and on the ESC website. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 29, 2015 Category: Global & Universal Source Type: news

EHR Data Predicts Risk of Readmission After PCIEHR Data Predicts Risk of Readmission After PCI
Patient characteristics derived from electronic health records (EHR) can predict the risk of readmission after percutaneous coronary intervention (PCI), a study suggests. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 21, 2015 Category: Consumer Health News Tags: Internal Medicine News Source Type: news

Abiomed partners with Fenway Park
Abiomed (NSDQ:ABMD) said today it entered into a corporate partnership with Boston’s Fenway Park, and will bring its Impella mobile learning lab to the stadium tomorrow. The lab will be parked at Fenway so individuals in healthcare and medical fields can learn about its Impella heart pump, which the Danvers, Mass.-based company says is the world’s smallest. “We are delighted to form a partnership with this leader in the medical technology industry. Abiomed is helping to recover hearts and save lives with its innovative technology and helping the Massachusetts economy by expanding its headquarters locally....
Source: Mass Device - August 11, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Cardiac Implants Cardiovascular Abiomed Inc. Source Type: news

Triple Therapy for High-Risk Older Adults Undergoing PCI? Not So Fast (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH For older adults with atrial fibrillation and acute MI who undergo percutaneous coronary intervention (PCI), treatment with dual antiplatelet therapy (DAPT) plus warfarin (so-called triple therapy) appears to offer little cardiovascular benefit over DAPT alone — and … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 4, 2015 Category: Primary Care Source Type: news

Kengreal (cangrelor) for Reducing Thrombotic Events During Percutaneous Coronary Intervention (PCI)
Kengreal (cangrelor) is the first and only intravenous anti-platelet agent indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing thrombotic events. (Source: Drug Development Technology)
Source: Drug Development Technology - June 30, 2015 Category: Pharmaceuticals Source Type: news

New Antiplatelet Drug Approved for Heart Surgery
FDA approves Kengreal for adult patients undergoing percutaneous coronary intervention (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 22, 2015 Category: Pharmaceuticals Source Type: news

FDA approves new antiplatelet drug used during heart procedure
The U.S. Food and Drug Administration today approved Kengreal (cangrelor), an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries, the blood vessels that supply blood to the heart. It is approved for adult patients undergoing percutaneous coronary intervention (PCI), a procedure used to open a blocked or narrowed coronary artery to improve blood flow to the heart muscle. (Source: Food and Drug Administration)
Source: Food and Drug Administration - June 22, 2015 Category: American Health Source Type: news

Sleep apnea common among patients undergoing heart procedure
Patients undergoing percutaneous coronary intervention (PCI), a coronary artery widening procedureused to treat heart disease, are at high risk for obstructive sleep apnea. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 18, 2015 Category: Science Source Type: news

Cangrelor Finally Gets Nod from FDA Advisory Panel (FREE)
By Larry Husten Edited by William E. Chavey, MD, MS An FDA advisory panel voted 9-2-1 on Wednesday to recommend approval of cangrelor during percutaneous coronary intervention to reduce the risk for periprocedural thrombotic events, … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 17, 2015 Category: Primary Care Source Type: news

Traditional risk factors raise cardiovascular risk in PsA
Psoriatic arthritis is associated with higher rates of self-reported angina pectoris, percutaneous coronary intervention, hypertension, obesity, and smoking than are observed in the general population, a large population-based cohort study found. However, the overall rate of cardiovascular (CV)... (Source: Skin and Allergy News)
Source: Skin and Allergy News - April 2, 2015 Category: Dermatology Tags: CME-candidate RHEUM Journal RHEUM News RHEUM Spondyloarthropathies RHEUM Psoriatic arthritis SAN Journals SAN Clinical News Source Type: news